Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daromun neoadjuvant intratumoral therapy versus surgery plus adjuvant therapy in resectable stage IIIB/C melanoma
2023-507119-36-00Phase 3Authorised
- Sponsor
- Philogen
- Start
- May 2022
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of onfekafusp alfa and darleukin in cutaneous melanoma (CM) (2 arms), sponsored by Philogen. Primary endpoint: Recurrence-free survival. Planned start May 2022; status: authorised.
02
Drugs
onfekafusp alfadarleukin
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2023-507119-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507119-36-00.